Expand ARWR Menu
ARWR MENU

ARWR Latest Press Releases

-- July 24, 2024 --

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results Business Wire 7:30 AM

-- June 25, 2024 --

Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial Business Wire 1:55 PM

-- June 24, 2024 --

Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE Business Wire 7:30 AM

-- June 3, 2024 --

Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome Business Wire 7:30 AM

-- May 31, 2024 --

Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences Business Wire 7:30 AM

-- May 29, 2024 --

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia Business Wire 5:30 AM

-- May 28, 2024 --

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia Business Wire 6:04 AM

-- May 20, 2024 --

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma Business Wire 6:00 AM

-- May 9, 2024 --

Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results Business Wire 4:01 PM

-- May 2, 2024 --

Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma Business Wire 4:01 PM

-- April 29, 2024 --

Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences Business Wire 7:30 AM

-- April 26, 2024 --

Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars Business Wire 7:30 AM

-- April 24, 2024 --

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results Business Wire 4:01 PM
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease Business Wire 7:30 AM

-- April 16, 2024 --

Turnstone Biologics Appoints William Waddill to its Board of Directors Globe Newswire 9:00 AM

-- April 7, 2024 --

Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo Business Wire 9:00 AM

-- April 1, 2024 --

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Business Wire 4:30 PM

-- March 25, 2024 --

Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data Business Wire 8:00 AM

-- March 8, 2024 --

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy Business Wire 7:30 AM

-- March 4, 2024 --

Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences Business Wire 7:30 AM